The World Health Organization (WHO) has approved the MVA-BN vaccine, developed by Bavarian Nordic A/S, marking it as the first-ever mpox vaccine to be added to the WHO’s prequalification list.
This significant approval is set to enhance global access to the vaccine, especially in regions experiencing urgent outbreaks like Africa. The move aims to aid efforts in reducing transmission and controlling the spread of mpox, a disease that has raised concerns due to recent outbreaks.
“This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in the future,” said WHO Director-General Tedros Adhanom Ghebreyesus. He emphasized the urgency of scaling up vaccine procurement and distribution to ensure equitable access for those most at risk.
The MVA-BN vaccine is administered in two doses, four weeks apart, to adults aged 18 and over. According to current data, the vaccine is 76 percent effective after a single dose and 82 percent effective after two doses. The WHO highlighted the necessity for continued data collection on the vaccine’s safety and effectiveness.
Yukiko Nakatani, WHO Assistant Director-General, noted that the prequalification decision will accelerate procurement by international agencies and expedite national regulatory approvals. “This will help speed up access to the vaccine where it is needed most,” she added.
The WHO’s approval is expected to bolster international efforts to combat mpox, contributing significantly to public health initiatives in affected regions. As the world navigates the challenges of emerging diseases, this development represents a hopeful stride towards better preparedness and response.
Reference(s):
cgtn.com
